Citadel Advisors’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Citadel Advisors’s Portfolio PRNB Stock Details PRNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-801,539	Closed	-$47.9M	–	11106
2020 Q2	$47.9M	Sell	801,539 -33,676	-4%	-$2.08M	0.02%	830
2020 Q1	$49.6M	Buy	835,215 +690,755	+478%	+$40.3M	0.02%	648
2019 Q4	$7.91M	Buy	144,460 +136,564	+1,730%	+$5.1M	﹤0.01%	2482
2019 Q3	$223K	Buy	+7,896	New	+$290K	﹤0.01%	8016
2018 Q4	–	Sell	-7,206	Closed	-$211K	–	10086
2018 Q3	$211K	Buy	+7,206	New	+$203K	﹤0.01%	8143

Other funds holding PRNB

Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $34B AUM 40.73% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $2.66B AUM 26.2% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $28.9B AUM 44.1% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ADL

Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return

Citadel Advisors's PRNB Position: Q3 2020 in Review

Citadel Advisors sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 801,539 shares — an estimated $47.9M sold.

Citadel Advisors first reported a position in PRNB in Q3 2018 and held it in 5 quarters. The position peaked at $49.6M in Q1 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

Citadel Advisors reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Citadel Advisors sold 801,539 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $47.9M.
Citadel Advisors first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 5 quarters.
Citadel Advisors's Principia Biopharma Inc. Common Stock position peaked at $49.6M in Q1 2020.
9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Citadel Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.